Zymeworks Inc. (ZYME), a biotechnology company, announced on Tuesday receipt of approval from the U.S. Food and Drug Administration (FDA) for Ziihera in two combination regimens for treating HER2+ gastroesophageal adenocarcinoma.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.